Clinical Trials Logo

Clinical Trial Summary

chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis, induction of cytotoxic autophagy, inhibition of glutamate and DRD2 receptors. This study will evaluate the addition of chlorpromazine to the first-line therapeutic protocol in colon cancer stage III.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05433402
Study type Interventional
Source Sadat City University
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date July 20, 2022
Completion date September 30, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT00309530 - Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C Phase 3
Completed NCT04342676 - Lymph Node Ratio and Kras Mutation in R Colon Cancer Phase 3
Enrolling by invitation NCT05179889 - Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer Phase 2/Phase 3
Recruiting NCT06108310 - ArTificial inTelligence-based RAdiogenomics in Colon Tumors
Withdrawn NCT05310565 - The Effects of Chiropractic in Adults With Colon Cancer N/A
Not yet recruiting NCT04488159 - Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer Phase 3
Recruiting NCT05194878 - Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers Phase 3